Clinical Trial Update: A Study of the Plasmodium Falciparum Malaria Vaccine Candidate Pfs48/45 in Matrix-M Adjuvant in the UK [EARLY_Phase 1]

View source ↗

Summary

Early-phase 1 study of the Pfs48/45 malaria vaccine candidate with Matrix-M adjuvant in the UK was terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malaria
• Plasmodium Falciparum Malaria

Drugs mentioned

• Pfs48/45 malaria vaccine candidate with Matrix-M adjuvant

Snippet

Sponsor: University of Oxford | Conditions: Malaria, Plasmodium Falciparum | EARLY_Phase 1 | Status: TERMINATED | Results posted: 2025-03-28